Literature DB >> 15650506

Pediatric bupropion-induced serum sicknesslike reaction.

Sabine Hack1.   

Abstract

This reports the first 2 cases of serum sicknesslike reaction to bupropion in children (age 12 and 14). Serum sicknesslike reactions are an example of immune-complex medicated disease. The cardinal symptoms of serum sickness are fever, lymphadenopathy, arthralgias or arthritis, and urticaria. Symptoms usually resolve without long-term sequela following discontinuation of the exogenous antigen. It is likely that serum sicknesslike reactions to bupropion are either relatively rare or underrecognized and underreported. Between May 1998 and May 2001, GlaxoSmith Kline received 172 reports of seizures (a well-known adverse drug reaction) and only 37 reports of serum sicknesslike reactions (Wooltorton 2002). We do not know if children and adolescents are more prone than adults to develop serum sicknesslike reactions to bupropion. Luckily, the reported cases of serum sicknesslike reactions to bupropion have not caused irreversible morbidity or mortality. Nevertheless, the symptoms are painful, temporarily disfiguring and disabling, and warrant prompt medical attention. Parents and patients should be educated about this potential side effect at the onset of treatment, because symptoms are similar to many infectious childhood illnesses, and the treatment of serum sicknesslike reactions to bupropion should include the discontinuation of bupropion.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15650506     DOI: 10.1089/cap.2004.14.478

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  2 in total

1.  Monoarthritis Induced by Bupropion Hydrochloride.

Authors:  Weiqing Yuan; Barry N Williams
Journal:  Psychopharmacol Bull       Date:  2011-05-15

2.  Delayed onset urticaria in depressive patients with bupropion prescription: a nationwide population-based study.

Authors:  Li-Yu Hu; Chia-Jen Liu; Ti Lu; Tsung-Ming Hu; Chia-Fen Tsai; Yu-Wen Hu; Cheng-Che Shen; Yu-Sheng Chang; Mu-Hong Chen; Chung-Jen Teng; Huey-Ling Chiang; Chiu-Mei Yeh; Vincent Yi-Fong Su; Wei-Shu Wang; Pan-Ming Chen; Tzeng-Ji Chen; Tung-Ping Su
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.